CA2526433C - Agent therapeutique possedant un marqueur de consommation quantitative et methode de surveillance de la consommation de l'agent therapeutique - Google Patents

Agent therapeutique possedant un marqueur de consommation quantitative et methode de surveillance de la consommation de l'agent therapeutique Download PDF

Info

Publication number: CA2526433C
Authority: CA; Canada
Prior art keywords: urine; compliance; patient; marker; medication
Prior art date: 1996-09-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2526433A

Other languages

English (en)

Other versions

CA2526433A1 (fr

Inventor

Michael Kell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

U D Testing Inc

Original Assignee

U D Testing Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-17

Filing date

1997-09-17

Publication date

2010-08-03

1996-09-17 Priority claimed from US08/715,016 external-priority patent/US5776783A/en

1997-09-17 Application filed by U D Testing Inc filed Critical U D Testing Inc

1998-03-26 Publication of CA2526433A1 publication Critical patent/CA2526433A1/fr

2010-08-03 Application granted granted Critical

2010-08-03 Publication of CA2526433C publication Critical patent/CA2526433C/fr

2017-09-17 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000003814 drug Substances 0.000 title claims abstract description 136
239000003550 marker Substances 0.000 title claims abstract description 111
229940124597 therapeutic agent Drugs 0.000 title claims description 17
238000000034 method Methods 0.000 title abstract description 40
238000012544 monitoring process Methods 0.000 title abstract description 26
229940049706 benzodiazepine Drugs 0.000 claims abstract description 18
239000002253 acid Substances 0.000 claims abstract description 5
210000002700 urine Anatomy 0.000 claims description 191
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical group N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 24
229960003529 diazepam Drugs 0.000 claims description 22
239000000203 mixture Substances 0.000 claims description 20
239000002207 metabolite Substances 0.000 claims description 17
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 10
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical group C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
229960004538 alprazolam Drugs 0.000 claims description 2
229940079593 drug Drugs 0.000 abstract description 116
239000000126 substance Substances 0.000 abstract description 17
-1 acids benzodiazepines Chemical class 0.000 abstract description 2
239000002547 new drug Substances 0.000 abstract description 2
230000005484 gravity Effects 0.000 description 61
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 52
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 41
229960001797 methadone Drugs 0.000 description 41
239000000523 sample Substances 0.000 description 28
229940109239 creatinine Drugs 0.000 description 26
238000004519 manufacturing process Methods 0.000 description 21
238000002483 medication Methods 0.000 description 19
238000012360 testing method Methods 0.000 description 19
238000002474 experimental method Methods 0.000 description 15
230000008859 change Effects 0.000 description 13
239000006187 pill Substances 0.000 description 12
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
239000008103 glucose Substances 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
208000019901 Anxiety disease Diseases 0.000 description 8
230000037396 body weight Effects 0.000 description 8
238000009472 formulation Methods 0.000 description 8
238000004458 analytical method Methods 0.000 description 7
230000036506 anxiety Effects 0.000 description 7
150000001557 benzodiazepines Chemical class 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000005259 measurement Methods 0.000 description 7
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
230000037406 food intake Effects 0.000 description 6
210000003734 kidney Anatomy 0.000 description 6
238000011160 research Methods 0.000 description 6
230000002485 urinary effect Effects 0.000 description 6
230000001419 dependent effect Effects 0.000 description 5
230000029142 excretion Effects 0.000 description 5
230000006870 function Effects 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
238000012423 maintenance Methods 0.000 description 5
239000000975 dye Substances 0.000 description 4
229940005483 opioid analgesics Drugs 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
238000012937 correction Methods 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000007877 drug screening Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
235000013305 food Nutrition 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
231100000283 hepatitis Toxicity 0.000 description 3
239000005556 hormone Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
230000003907 kidney function Effects 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
239000000047 product Substances 0.000 description 3
210000005227 renal system Anatomy 0.000 description 3
229960002477 riboflavin Drugs 0.000 description 3
235000019192 riboflavin Nutrition 0.000 description 3
239000002151 riboflavin Substances 0.000 description 3
239000011800 void material Substances 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000007792 addition Methods 0.000 description 2
229940125717 barbiturate Drugs 0.000 description 2
235000013361 beverage Nutrition 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000013329 compounding Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
229940084926 diazepam 2 mg Drugs 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
239000003777 experimental drug Substances 0.000 description 2
230000024924 glomerular filtration Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
239000002117 illicit drug Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
206010033296 Overdoses Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
208000004793 anterograde amnesia Diseases 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000007844 bleaching agent Substances 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940121657 clinical drug Drugs 0.000 description 1
238000009535 clinical urine test Methods 0.000 description 1
239000012468 concentrated sample Substances 0.000 description 1
238000009223 counseling Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000035622 drinking Effects 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
239000002359 drug metabolite Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000037870 generalized anxiety Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
230000002673 intoxicating effect Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229960005189 methadone hydrochloride Drugs 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000036280 sedation Effects 0.000 description 1
230000004799 sedative–hypnotic effect Effects 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
238000004088 simulation Methods 0.000 description 1
238000009987 spinning Methods 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
229940072690 valium Drugs 0.000 description 1
238000012795 verification Methods 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1
239000000052 vinegar Substances 0.000 description 1

Landscapes

Investigating Or Analysing Biological Materials (AREA)
Medical Treatment And Welfare Office Work (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)

CA2526433A 1996-09-17 1997-09-17 Agent therapeutique possedant un marqueur de consommation quantitative et methode de surveillance de la consommation de l'agent therapeutique Expired - Fee Related CA2526433C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/715,016 US5776783A (en)	1993-11-02	1996-09-17	Method of monitoring therapeutic agent consumption
US08/715,016		1996-09-17
CA002265795A CA2265795C (fr)	1996-09-17	1997-09-17	Agent therapeutique possedant un marqueur de consommation quantitative et methode de surveillance de la consommation de l'agent therapeutique

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002265795A Division CA2265795C (fr)	1996-09-17	1997-09-17	Agent therapeutique possedant un marqueur de consommation quantitative et methode de surveillance de la consommation de l'agent therapeutique

Publications (2)

Publication Number	Publication Date
CA2526433A1 CA2526433A1 (fr)	1998-03-26
CA2526433C true CA2526433C (fr)	2010-08-03

Family

ID=35851943

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2526433A Expired - Fee Related CA2526433C (fr)	1996-09-17	1997-09-17	Agent therapeutique possedant un marqueur de consommation quantitative et methode de surveillance de la consommation de l'agent therapeutique

Country Status (1)

Country	Link
CA (1)	CA2526433C (fr)

1997
- 1997-09-17 CA CA2526433A patent/CA2526433C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2526433A1 (fr)	1998-03-26

Legal Events

Date	Code	Title	Description
2005-12-05	EEER	Examination request
2014-10-29	MKLA	Lapsed	Effective date: 20140917

Publication	Publication Date	Title
US5776783A (en)	1998-07-07	Method of monitoring therapeutic agent consumption
US5908788A (en)	1999-06-01	Method of monitoring patient compliance with medications prescriptions
US5547878A (en)	1996-08-20	Method of monitoring patient compliance with medications prescriptions
US6136801A (en)	2000-10-24	Therapeutic agent with quantitative consumption marker
Crom et al.	1994	Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia
Leppik et al.	1979	Compliance and variability of plasma phenytoin levels in epileptic patients
Guth et al.	1978	Measurement of gastric mucosal blood flow in man
Halikas et al.	1991	Cocaine reduction in unmotivated crack users using carbamazepine versus placebo in a short‐term, double‐blind crossover design
US6790668B1 (en)	2004-09-14	Monitoring patient compliance and bioavailability of drugs by deproteinizing body fluids
WO1999002983A1 (fr)	1999-01-21	Procede de diagnostic de la falsification de l'urine
McCarron et al.	1984	Detection of phencyclidine usage by radioimmunoassay of saliva
US6124136A (en)	2000-09-26	Method of monitoring compliance with methadone treatment program
CA2216380C (fr)	2003-02-04	Methode de determination des clairances renales
Dubbert et al.	1985	Riboflavin as a tracer of medication compliance
EP2533768B1 (fr)	2015-07-22	Méthodes permettant de normaliser des concentrations d'oxycodone mesurées et de détecter la non-observation d'un traitement thérapeutique
CA2526433C (fr)	2010-08-03	Agent therapeutique possedant un marqueur de consommation quantitative et methode de surveillance de la consommation de l'agent therapeutique
AU736645B2 (en)	2001-08-02	Therapeutic agent with quantitative consumption marker and method of monitoring therapeutic agent consumption
AU758193B2 (en)	2003-03-20	Therepeutic agent with quantitative consumption marker
US5500372A (en)	1996-03-19	Method of determining renal clearances
Kell	1994	Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting
Shvartsburd et al.	1983	Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients
Wolff et al.	1999	Specific laboratory investigations for assessments and management of drug problems
Piergies et al.	1997	Lack of cross-reactivity of Ambien (zolpidem) with drugs in standard urine drug screens
Mollica	1984	Monitoring compliance through analysis of drug and metabolite levels
Alshouha et al.	2025	Saliva versus plasma therapeutic drug monitoring of carbamazepine in Jordanian patients